Patents by Inventor HUI DIAO
HUI DIAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170143757Abstract: Disclosed herein are compounds and compositions useful for reducing the risk of infection. In particular, disclosed herein are mandelic acid condensation polymers, compositions comprising such compounds, processes for producing such compounds, and methods of using such compounds.Type: ApplicationFiled: November 28, 2016Publication date: May 25, 2017Inventors: Robert A. Anderson, JR., Xiao-Hui Diao, Lourens J.D. Zaneveld, Calvin J. Chany, II, Aleksej Krunic, Donald P. Waller, Duane L. Venton, Sanjay Jain
-
Patent number: 9527793Abstract: Disclosed herein are compounds and compositions useful for reducing the risk of infection. In particular, disclosed herein are mandelic acid condensation polymers, compositions comprising such compounds, processes for producing such compounds, and methods of using such compounds.Type: GrantFiled: November 30, 2012Date of Patent: December 27, 2016Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, RUSH UNIVERSITY MEDICAL CENTERInventors: Robert A. Anderson, Jr., Xiao-Hui Diao, Lourens J. D. Zaneveld, Calvin J. Chany, II, Aleksej Krunic, Donald P. Waller, Duane L. Venton, Sanjay Jain
-
Publication number: 20140371310Abstract: Disclosed herein are compounds and compositions useful for reducing the risk of infection. In particular, disclosed herein are mandelic acid condensation polymers, compositions comprising such compounds, processes for producing such compounds, and methods of using such compounds.Type: ApplicationFiled: November 30, 2012Publication date: December 18, 2014Inventors: Robert A. Anderson, JR., Xiao-Hui Diao, Lourens J.D. Zaneveld, Calvin J. Chany, II, Aleksej Krunic, Donald P. Waller, Duane L. Venton, Sanjay Jain
-
Publication number: 20120155644Abstract: A method for communicating end-to-end encrypted super group information is provided. Temporary address data, which identifies a temporary address on which the super group is to communicate, is transmitted from a gateway to a back-to-back communications device using a direct mode or data message. The back-to-back communications device retrieves an encryption key associated with the temporary address and uses the encryption key to decrypt super group information sent from a networked communications device on the temporary address. The back-to-back communications reverts back to its original encryption key when super group communications are terminated.Type: ApplicationFiled: December 20, 2010Publication date: June 21, 2012Applicant: MOTOROLA, INC.Inventors: MARK J. WEALLEANS, HUI DIAO, KRISTIAN GRONKJAER PEDERSEN
-
Patent number: 6239182Abstract: A method for the reduction in the risk of transmitting a sexually transmitted disease—especially HIV and/or HSV—during sexual activity is provided. This method generally comprises the application of an effective amount of an inhibitory agent, preferably as a topical formulation, to the area or areas of sexual contact prior to engaging in sexual activity. Inhibitory agents which are useful in the present invention include, for example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H2SO4-modified mandelic acids, and the like. This method can be used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide variety of sexual activities. In addition to anti-STD activity, these agents may also act as vaginal contraceptives; moreover, they generally have fewer side effects than conventional vaginal contraceptives (e.g., nonoxynol-9).Type: GrantFiled: February 18, 1999Date of Patent: May 29, 2001Assignee: Rush-Presbyterian-St. Lukes Medical CenterInventors: Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Jr., Xiao Hui Diao, Paul Robert Young, Jr., Donald Paul Waller, Sanjay Garg, Calvin J. Chany, II
-
Patent number: 6028115Abstract: A method for the reduction in the risk of transmitting a sexually transmitted disease--especially HIV and/or HSV--during sexual activity is provided. This method generally comprises the application of an effective amount of an inhibitory agent, preferably as a topical formulation, to the area or areas of sexual contact prior to engaging in sexual activity. Inhibitory agents which are useful in the present invention include, for example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H.sub.2 SO.sub.4 -modified mandelic acids, and the like. This method can be used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide variety of sexual activities. In addition to anti-STD activity, these agents may also act as vaginal contraceptives; moreover, they generally have fewer side effects than conventional vaginal contraceptives (e.g., nonoxynol-9).Type: GrantFiled: February 3, 1999Date of Patent: February 22, 2000Assignee: Rush-Presbyterian-St. Luke's Medical CenterInventors: Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Jr., Xiao Hui Diao, Paul Robert Young, Jr., Donald Paul Waller, Sanjay Garg, Calvin J. Chany, II
-
Patent number: 5932619Abstract: A method for the reduction in the risk of transmitting a sexually transmitted disease--especially HIV and/or HSV--during sexual activity is provided. This method generally comprises the application of an effective amount of an inhibitory agent, preferably as a topical formulation, to the area or areas of sexual contact prior to engaging in sexual activity. Inhibitory agents which are useful in the present invention include, for example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H.sub.2 SO.sub.4 -modified mandelic acids, and the like. This method can be used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide variety of sexual activities. In addition to anti-STD activity, these agents may also act as vaginal contraceptives; moreover, they generally have fewer side effects than conventional vaginal contraceptives (e.g., nonoxynol-9).Type: GrantFiled: November 7, 1997Date of Patent: August 3, 1999Assignee: Rush-Presbyterian, St. Luke's Medical CenterInventors: Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Jr., Xiao Hui Diao, Paul Robert Young, Jr., Donald Paul Waller, Sanjay Garg, Calvin J. Chany, II, Darrick S. H. L. Kim
-
Patent number: 5925621Abstract: A method for the reduction in the risk of transmitting a sexually transmitted disease--especially HIV and/or HSV--during sexual activity is provided. This method generally comprises the application of an effective amount of an inhibitory agent, preferably as a topical formulation, to the area or areas of sexual contact prior to engaging in sexual activity. Inhibitory agents which are useful in the present invention include, for example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H.sub.2 SO.sub.4 -modified mandelic acids, and the like. This method can be used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide variety of sexual activities. In addition to anti-STD activity, these agents may also act as vaginal contraceptives; moreover, they generally have fewer side effects than conventional vaginal contraceptives (e.g., nonoxynol-9).Type: GrantFiled: October 14, 1997Date of Patent: July 20, 1999Assignee: Rush-Presbyterian, St. Luke's Medical CenterInventors: Lourens Jan Dirk Zaneveld, Robert Anthony Anderson, Jr., Xiao Hui Diao, Paul Robert Young, Jr., Donald Paul Waller, Sanjay Garg, Calvin J. Chany, II